Consensus statement. Corticosteroid therapy in ENT in the context of the COVID-19 pandemic.
Fiche publication
Date publication
mai 2020
Journal
European annals of otorhinolaryngology, head and neck diseases
Auteurs
Membres identifiés du Cancéropôle Est :
Pr GALLET Patrice
Tous les auteurs :
Herman P, Vincent C, Parietti Winkler C, Loundon N, Couloigner V, Tankere F, Tringali S, Gallet P, Papon JF, Montava M, Lavieille JP, Charpiot A, Schmerber S
Lien Pubmed
Résumé
This consensus statement about the indications and modalities of corticosteroid treatment in the context of the COVID-19 pandemic was jointly written by experts from the French Association of Otology and Oto-Neurology (AFON) and from the French Society of Otorhinolaryngology, Head and Neck Surgery (SFORL). There is currently not enough data in favour of danger or benefit from corticosteroids in COVID-19, so until this matter is resolved it is advisable to limit their indications to the most serious clinical pictures for which it is well established that this type of treatment has a positive impact on the progression of symptoms. In Grade V and VI Bell's palsy according to the House-Brackmann grading system, a week's course of oral corticosteroids is recommended. Corticosteroid therapy is also recommended in cases of sudden hearing loss of more than 60dB, either in the form of intratympanic injections or a week's course of oral medication. In rhinology, there is no indication for systemic corticosteroid therapy in the current situation. However, patients are advised to continue with their local corticosteroid therapy in the form of a nasal spray or by inhalation. Treatments with corticosteroid nasal sprays can still be prescribed if there is no alternative. Finally, systemic or local corticosteroid therapy is not indicated for bacterial ENT infections.
Mots clés
Anosmia, Bell's palsy, COVID-19, Prednisone, SARS-CoV-2, Sudden hearing loss
Référence
Eur Ann Otorhinolaryngol Head Neck Dis. 2020 May 4;: